Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro in the 41M The 4lMcisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium adenosine triphosphatase (Na+, K+-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na+, K+-ATPase levels, and Na+ potential across the plasma membrane. Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examined. The data suggests that increased accumulation of these compounds, as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.
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Summary
Acquired resistance to cisplatin (cis-diamminedichloroplatinum (II)) has been generated in vitro in the 41M human ovarian carcinoma cell line, established from a previously untreated patient. Three cisplatin-resistant variants were selected at approximately 2, 4 and 6-fold resistance (in terms of 50% inhibitory concentrations), in order to study the underlying mechanisms of acquired cisplatin resistance. Compared to the parent line, platinum accumulation following exposure to equimolar concentrations of cisplatin was on average (across the entire concentration range) 2.9, 3.6 and 4.8-fold lower in the 41McisR2, 4lMcisR4 and 41McisR6 cell lines, respectively. Thus the difference in uptake corresponded closely with their resistance factor in the three resistant variants. Moreover, a significant reduction in platinum accumulation was observed as early as 5 min after exposure to cisplatin in the 41 M vs 41 McisR6 cell lines. Platinum accumulation was similar in all cell lines following exposure to equitoxic concentrations (2 h IC50) of cisplatin.
Enhanced efflux of drug was not observed between the 41 M and 41 McisR6 cells. In addition, there was no difference in intracellular glutathione (GSH) levels. Our previous studies have shown no indication of metallothionein involvement and the decrease in cisplatin uptake in the 4lMcisR6 cells was reflected by a similar reduction in DNA interstrand cross-links (ISC) formation. These results suggest that the mechanism of acquired resistance to cisplatin in the 4lMcisR6 cell line may be predominantly due to reduced drug uptake. The 4lMcisR6 cells were not found to be cross-resistant to ouabain, a postulated specific inhibitor of sodium-potassium adenosine triphosphatase (Na+, K+-ATPase), suggesting that decreased cisplatin accumulation in these cells is probably not regulated by alterations in their Na+, K+-ATPase levels, and Na+ potential across the plasma membrane. Cellular accumulation of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates, which exhibit enhanced cytotoxicity over cisplatin and completely circumvent resistance to cisplatin in the 41McisR line, was also examined. The data suggests that increased accumulation of these compounds, as a result of their enhanced lipophilicity, could account for the dramatic increase in their potency over cisplatin.
Cisplatin is a widely used anticancer drug, particularly in the treatment of human ovarian, testicular, bladder, and head and neck cancers (Loehrer & Einhorn, 1984; Calvert et al., 1985) . However, the emergence of drug resistance in the tumour cells and the unfavourable toxicity profile of cisplatin (primarily nephrotoxicity) still reduces its efficacy Hromas et al., 1987) . The second generation drug, carboplatin, although devoid of the major toxic limitations of the parent drug (Harrap, 1985) , has a similar spectrum of antitumour activity. Hence, there is an urgent need for developing platinum drugs which are capable of circumventing cisplatin/carboplatin resistance.
Many studies have reported several potential biochemical mechanisms of cisplatin resistance. They have focused on descriptions of cross-resistance, differences in intracellular detoxification, decreased chromatin binding, reduced DNA damage and enhanced DNA repair mechanisms, and reduced drug accumulation, typically between established pairs of sensitive and acquired cisplatin-resistance variant cell lines (for reviews see Richon & Eastman, 1986; De Graeff et al., 1988; Andress & Howell, 1990) .
A positive correlation has been observed between cisplatin cytotoxicity and accumulation in tumour cells (EichholtzWirth & Hietel, 1986; Metcalfe et al., 1986) . Many studies have implicated a platinum accumulation defect as an important mechanism of cisplatin resistance in both murine (Hromas et al., 1987; Kraker & Moore, 1988) and human carcinoma cell lines (Teicher et al., 1987; Andrews et al., 1988; Mann et al., 1990) . Moreover, this may occur at an early stage during development of cisplatin resistance (Andrews et al., 1988; . It should be noted, however, that some cell lines with cisplatin resistance do not show any difference in accumulation (e.g., GLC4-CDDP human small cell lung Hospers et al., 1988) . The exact mechanism of cisplatin transport into cells is unknown. It has been postulated that cisplatin enters cells by passive diffusion. However, studies have shown that cisplatin accumulation can be modulated by various treatments which suggests that transport mechanisms other than simple passive diffusion may be involved .
Cellular resistance may either be present at the onset of treatment (intrinsic) or develop after an initial response (acquired). Our platinum-based drug discovery program, is aimed at developing a new generation of platinum analogues, capable of circumventing both intrinsic and acquired resistance to cisplatin and to broaden its clinical spectrum of activity. To assist in these objectives, we are establishing in vitro and in vivo screening models exhibiting intrinsic and acquired resistance to cisplatin, and determining mechanisms of resistance in these models. We have selected a sensitive human ovarian carcinoma cell line, 41M, which was established from a previously untreated patient, and developed sublines with varying degrees of resistance to cisplatin. We have examined differences in cisplatin accumulation, drug efflux, and GSH levels in these cell lines. As two previous reports have suggested a role for the membrane-bound Na+, K+-ATPase in cisplatin uptake (Kawai et al., 1987; Andrews et al., 1991) we determined the cytotoxicity of ouabain, a postulated specific inhibitor of the Na+, K+-ATPase, in these cell lines. In addition, the cytotoxicity of a novel class of platinum (IV) ammine/cyclohexylamine dicarboxylates and a Pt (II) complex, JM 118 (cis-amminedichloro (cyclohexylamine) platinum (II)), which exhibit dramatic and selective cytotoxic activity in cisplatin-refractory cell lines Kelland et al., 1992a) , has been determined. The accumulation of these complexes in the sensitive and resistant cell lines was also compared with that of cisplatin. (Giandomenico et al., 1991) . The structures of the platinum complexes and the generalised structure of platinum (IV) ammine/cyclohexylamine dicarboxylates used in this study are shown in Figure  1 . Ouabain octahydrate and all other chemicals were purchased from Sigma Chemicals UK Ltd.
Cell lines
The human ovarian carcinoma cell line, 41M, used in this study was derived from a previously untreated patient. Details of its biological properties have been described previously (Hills et al., 1989) . This cell line was made resistant to cisplatin by continuously exposing cells to increasing concentrations of drug (up to a maximum of 1 tLM) over a 15-month period. Cell lines (4lMcisR2, 4IMcisR4, 4IMcisR6) with approximately 2-fold, 4-fold and 6-fold degrees of resistance respectively, were generated. Cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM) augmented to contain 10% fetal calf serum (Imperial Laboratories, Andover, UK), 50 lAg ml-' gentamicin, 2.5 fig ml-' amphotericin B, 2 mM L-glutamine, 10 fg ml-' insulin, and 0.5 tg ml-' hydrocortisone in a 10% C02, 90% air atmosphere. Cells were periodically checked and were found to be free of mycoplasma.
Assessment of cytotoxicity
All platinum agents were dissolved immediately before use in either 0.9% saline (at 500 LM for cisplatin, JM118, and JM216) or absolute ethanol (at 5 mM for the other platinum (IV) dicarboxylates). The final concentration of ethanol (0.5%) in the medium had no growth-inhibitory effect on the cells. Ouabain was dissolved in sterile water at 1 mM. Cytotoxicity was assessed as described recently Kelland et al., 1992a) The total GSH content of the cell lines were determined by an enzymatic assay utilising gluthathione reductase as described recently Figure 3 shows that platinum accumulation in the parent and three acquiredresistant variants was a linear function of cisplatin concentration up to at least 100 gM. In fact, lack of saturation of platinum accumulation was observed up to 500 tAM cisplatin (Table I ). In contrast, the intracellular platinum levels after exposure to equitoxic concentrations of cisplatin were found to be similar for all cell lines (Table I ). Figure 4 shows that following exposure to 100 jM cisplatin, platinum accumulation was linear over 60 min (r = 0.982) for 41M and over 120 min (r = 0.992) for 41McisR6. Additionally, a significant reduction in accumulation in the acquired-resistant variant was observed at the earliest time point of 5 min. The reduction ranged from 1.5-2.5-fold over the 120 min exposure period and was statistically significant at all times (P<0.0 1).
The time course for platinum efflux into drug-free medium was determined in 41M and 41McisR6 cell lines following a 30 min loading period at 50 and 200 jAM cisplatin (Figure 5a ) and 120 min at 50 gM cisplatin ( Figure Sb) . No significant diference in efflux of platinum was observed between the cell lines (P> 0.5 at each time point investigated). The amount of platinum which escaped from both cell lines (20-30%) was independent of whether the cells were loaded with 50 or 200 jiM cisplatin, or whether the cells were loaded for 30 or 120 min.
Accumulation of novel platinum (IV) complexes
To determine if enhanced cellular accumulation contributed to the lack of cross-resistance of platinum (II and IV) com- that reduced drug accumulation may play a major role in the mechanism of acquired resistance to cisplatin in these cell lines. The reduced drug accumulation appears to be caused by reduced uptake and not increased efflux since no significant differences in the loss of platinum was observed between the 41M and 4lMcisR6 cell lines. These results correspond to the findings of Teicher et al. (1987) and Waud (1987) . In contrast, Mann et al. (1990) reported that the rate constant for rapid efflux (within the first 5 min after a 10 min drug loading period) was 53% higher in resistant compared to parent 2008 human ovarian carcinoma cells.
The precise mechanism(s) by which cisplatin enters cells is unknown and both passive diffussion and carrier mediated transport have been implicated (for review see . We found that cisplatin accumulation was not saturable up to 500 gM which agrees with other studies in a variety of tissue types (Eichholtz-Wirth & Hietel, 1986; Hecquet et al., 1986; Hromas et al., 1987; Andrews et al., 1988) . Although this suggests that transport of cisplatin may occur Figure 5 Loss of cisplatin over a 120 min period from 41M (0) and 41McisR6 (A) cell lines preincubated with cisplatin. 41M and 41McisR6 cells were preincubated in 50 and 200 ylM cisplatin, respectively for 30 min a, and in 50 gM cisplatin for 120 min b. At the end of the preincubation period, cells were washed and incubated in drug-free medium for various times before determining the retained intracellular platinum levels as described in materials and methods. Error bars= s.d. of triplicate determinations in two experiments.
GSH concentrations Intracellular GSH was measured to determine if elevated levels contributed to the resistant phenotype as has been reported elsewhere (Arrick & Nathan, 1984; Green et al., 1984; Andrews et al., 1985; Louie et al., 1985) . There was no significant difference (P > 0.05) in GSH concentration between parent and acquired-resistant variants, in terms of either cell numbers or protein content (Table III) .
Discussion
Both intrinsic and acquired resistance to cisplatin limit the clinical utility of this valuable anticancer drug. Many studies have shown that decreased accumulation of cisplatin is an important factor in the in vitro and in vivo acquisition of resistance to this antitumour compound (Hromas et al., 1986; Richon & Eastman, 1986; Richon et al., 1987; Teicher et al., 1987; Kraker & Moore, 1988; . In the present study we examined the role of reduced drug accumulation as a possible mechanism of resistance to cisplatin in the acquired-resistant variants of a sensitive human ovarian carcinoma cell line (41M), which was established from a previously untreated patient. Intracellular platinum accumulation was significantly reduced in the acquired-resistant variants compared to the parent line. Furthermore, the several-fold reductions following exposure to equimolar concentrations of cisplatin closely paralleled the resistance factors to cisplatin. However, at equitoxic concentrations of cisplatin, similar amounts of platinum were accumulated in the parent and the resistant sublines. These results suggest primarily by passive diffusion, the involvement of carrier mediated transport cannot be ruled out. Several reports have shown that cisplatin accumulation can be modulated by various treatments (e.g., Kikuchi et al., 1990; Morikage et al., 1991) . In addition, specific changes in plasma membrane proteins have been reported in association with reduced cisplatin accumulation in resistant cells (Bernal et al., 1990; Kawai et al., 1990) . We are currently evaluating whether alterations in cell membranes are responsible for the reduced drug uptake in the acquired resistant 4lMcisR6 cell line. Recently both Kawai et al. (1987) and Andrews et al. (1991) have postulated a central role for Na+,K+-ATPase in cisplatin accumulation. This enzyme regulates the transmembrane Na+ gradients which in turn was found to partially regulate cisplatin accumulation in the 2008 human ovarian cell line (Andrews et al., 1991) . However, our results showed a lack of cross-resistance to ouabain, a postulated specific inhibitor of Na+,K+-ATPase, in the 4lMcisR6 cell line. This suggests that reduced drug accumulation in these cells is probably not regulated by an alteration in their Na+,K+-ATPase levels. Ammine/amine platinum (IV) dicarboxylates represent a novel class of antitumour complex which exhibit selective activity in cisplatin-refractory cell lines Kelland et al., 1992a) . Some of these dicarboxylates, especially those containing a total of 8 or more carbon atoms in their axial ligands, possess dramatic in vitro cytotoxic properties in human ovarian carcinoma cell lines (Kelland et al., 1992a) . Therefore, these compounds may provide a lead to the development of platinum drugs capable of circumventing cisplatin resistance. In this study we have compared the cytotoxicity of cisplatin with that of a platinum (II) complex (JM 118) and 4 platinum (IV) ammine/cyclohexylamine dicarboxylates in the 41M and 4lMcisR6 cell lines. The dicarboxylate complexes examined contained a range of 4-20 total number of axial carbon atoms. Interestingly, all these complexes (including JM118) were capable of circumventing acquired resistance to cisplatin in the 41McisR6 cell line and some were more potent than cisplatin in the parent cell line. To establish the mechanistic basis for their increased potency and lack of cross-resistance to cisplatin, we have compared the accumulation of these complexes with that of cisplatin in the sensitive and resistant cells. Our results indicated that the lack of cross-resistance may be attributable to the fact that the resistant cells were unable to retard the accumulation of these complexes. This may be related to their increased lipophilicity since accumulation of these dicarboxylates increased with increasing number of axial carbon atoms up to a total of 10. For example, while solubility in water (at 25°C) decreased along the series cisplatin (1183 gg ml 1), JM 118 (216 pg ml-'), JM216 (170 gg ml-'), and JM221 (75 JLg ml-'), solubility in octanol increased from 7.8 pg ml-' for cisplatin, to values of 37 for JM18, 54 for JM216, and 1317 for JM221. However, JM280, one of the most potent compounds with 20 axial carbon atoms, showed similar levels of accumulation to JM216, which contained only 4 axial carbon atoms.
Other factors involved in the mechanism of resistance such as intracellular detoxification through interaction with cellular thiols, or reduced Pt-DNA adduct formation and enhanced repair of DNA lesions must also be taken into account. Differences in GSH levels between sensitive and resistant cells cannot be implicated here, since none were found (Table III) . Whether reduced GSH contributes the acquired-resistant phenotype appears to be dependent upon cell type since some show differences between sensitive and resistant lines (e.g. Green et al., 1984; Louie et al., 1985) and others do not (e.g. Andrews et al., 1985) . We have reported previously that there was no direct involvement of intracellular metallothioneins in the mechanism of resistance, as indicated by the sensitivity of the cell lines to cadmium chloride (Loh et al., 1991) . Furthermore, the reduction in cisplatin uptake in 4lMcisR6 cells was reflected by a similar reduction in DNA interstrand crosslink formation, as measured by alkaline filter elution (Loh et al., 1991; Kelland et al., 1992b) .
In summary, reduced drug accumulation plays a major role in the mechanism of cisplatin acquired-resistance in the 4lMcisR6 cell line. Moreover, since reduced drug accumulation was observed in ancestors of this cell line with lower levels of resistance, it appears that this mechanism is involved at an early stage in the development of cisplatin resistance in these cells. Identification of alterations in plasma membranes of these cells could provide new strategies to circumvent cisplatin resistance caused by reduced drug accumulation. We have also shown, through use of the novel platinum (IV) ammine/cyclohexylamine dicarboxylate complexes, that resistance to cisplatin caused by reduced drug accumulation may be largely overcome by increasing the lipophilicity of the platinum agent. Such compounds could provide a lead to new 'third-generation' platinum containing agents to combat cancers currently resistant to cisplatin and which might exhibit a broader spectrum of antitumour activity.
